Year |
Citation |
Score |
2019 |
He F, Springer NL, Whitman MA, Pathi SP, Lee Y, Mohanan S, Marcott S, Chiou AE, Blank BS, Iyengar N, Morris PG, Jochelson M, Hudis CA, Shah P, Kunitake JAMR, et al. Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS). Biomaterials. 224: 119489. PMID 31546097 DOI: 10.1016/J.Biomaterials.2019.119489 |
0.351 |
|
2017 |
Kunitake JAMR, Choi S, Nguyen KX, Lee MM, He F, Sudilovsky D, Morris PG, Jochelson MS, Hudis CA, Muller DA, Fratzl P, Fischbach C, Masic A, Estroff LA. Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomas. Journal of Structural Biology. PMID 29221896 DOI: 10.1016/J.Jsb.2017.12.002 |
0.694 |
|
2017 |
He F, Chiou AE, Loh HC, Lynch M, Seo BR, Song YH, Lee MJ, Hoerth R, Bortel EL, Willie BM, Duda GN, Estroff LA, Masic A, Wagermaier W, Fratzl P, et al. Multiscale characterization of the mineral phase at skeletal sites of breast cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America. PMID 28923958 DOI: 10.1073/Pnas.1708161114 |
0.575 |
|
2011 |
Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Jänne PA, Hahn WC. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discovery. 1: 608-25. PMID 22586683 DOI: 10.1158/2159-8290.Cd-11-0046 |
0.301 |
|
2011 |
Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, He F, Moore FD, Clark OH, Ruan DT. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 96: E554-65. PMID 21190978 DOI: 10.1210/Mend.25.2.Zmg373A |
0.325 |
|
2010 |
Lin CI, Whang EE, Donner DB, Du J, Lorch J, He F, Jiang X, Price BD, Moore FD, Ruan DT. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Molecular Cancer Research : McR. 8: 1217-26. PMID 20736296 DOI: 10.1158/1541-7786.Mcr-10-0162 |
0.322 |
|
Show low-probability matches. |